| # | Drug | Count |
|---|---|---|
| 0 | OFATUMUMAB | 5 |
| 1 | PEMBROLIZUMAB | 5 |
| 2 | RESMETIROM | 5 |
| 3 | SECUKINUMAB | 5 |
| 4 | FLUOXETINE HYDROCHLORIDE | 4 |
| 5 | AGALSIDASE BETA | 3 |
| 6 | BEVACIZUMAB | 3 |
| 7 | CABOZANTINIB | 3 |
| 8 | DEXAMETHASONE | 3 |
| 9 | DEXAMETHASONE 1.5 MG | 3 |
| # | Drug | Count | Frequency |
|---|---|---|---|
| 0 | RESMETIROM | 5 | 0.0022 |
| 1 | BRODALUMAB | 2 | 0.0010 |
| 2 | RILONACEPT | 1 | 0.0009 |
| 3 | INOTUZUMAB OZOGAMICIN | 2 | 0.0007 |
| 4 | AGALSIDASE BETA | 3 | 0.0003 |
| 5 | ASCIMINIB | 1 | 0.0003 |
| 6 | IRINOTECAN HYDROCHLORIDE | 3 | 0.0002 |
| 7 | CALCIUM, MAGNESIUM, POTASSIUM, AND SODIUM OXYBATES | 2 | 0.0002 |
| 8 | ENCORAFENIB | 2 | 0.0002 |
| 9 | TRIFLURIDINE AND TIPIRACIL | 2 | 0.0002 |
| # | Drug class | Count | Frequency |
|---|---|---|---|
| 0 | Thyroid Hormone Receptor beta Agonist [EPC] | 5 | 0.0022 |
| 1 | Interleukin-17 Receptor A Antagonist [EPC] | 2 | 0.0010 |
| 2 | CD22-directed Immunoconjugate [EPC] | 2 | 0.0007 |
| 3 | Hydrolytic Lysosomal Neutral Glycosphingolipid-specific Enzyme [EPC] | 3 | 0.0003 |
| 4 | Interleukin-17A Antagonist [EPC] | 6 | 0.0002 |
| 5 | Asparagine-specific Enzyme [EPC] | 1 | 0.0001 |
| 6 | Programmed Death Receptor-1 Blocking Antibody [EPC] | 6 | 0.0001 |
| 7 | Antimetabolite Immunosuppressant [EPC] | 1 | 0.0000 |
| 8 | Epidermal Growth Factor Receptor Antagonist [EPC] | 2 | 0.0000 |
| 9 | Nucleoside Analog Antiviral [EPC] | 2 | 0.0000 |